» Articles » PMID: 37064155

Mu Opioid Receptor MRNA Overexpression Predicts Poor Prognosis Among 18 Common Solid Cancers: A Pan-cancer Analysis

Overview
Journal Front Oncol
Specialty Oncology
Date 2023 Apr 17
PMID 37064155
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Opioids are widely used for patients with solid tumors during surgery and for cancer pain relief. We conducted a pan-cancer genomic analysis to investigate the prognostic features of Mu opioid receptor () mRNA expression across 18 primary solid cancers.

Methods: All the data of cancer with mRNA were retrieved from cBioPortal for Cancer Genomics. Logistic regression was used to determine the associations between mRNA expression and clinicopathological features. Log-rank test and Cox regression was used for survival analysis. Subgroup analysis and propensity score matching were also carried out.

Results: 7,274 patients, including 1,112 patients with positive mRNA expression, were included for data analyses. Positive mRNA expression was associated with more advanced stage of T (adjusted Odds ratio [OR], 1.176; 95% confidence interval [CI], 1.022-1.354; =0.024), M (adjusted OR, 1.548; 95% CI, 1.095-2.189; =0.013) except N (adjusted OR, 1.145; 95% CI, 0.975-1.346; =0.101), and worse prognosis for overall survival (Hazard ratio [HR] 1.347, 95% CI 1.200-1.512, <0.001), progression-free survival (HR 1.359, 95% CI 1.220-1.513, <0.001), disease-free survival (HR 1.269, 95% CI 1.016-1.585, <0.001) and disease-specific survival (HR 1.474, 95% CI 1.284-1.693, <0.001). Patients with positive mRNA expression tended to be classified as tumor microenvironment immune types II, representing low PD-L1 and low CD8A expression.

Conclusion: mRNA overexpression is associated with poor prognosis and poor response to PD-L1 therapy.

Citing Articles

Impact of opioids and mu-opioid receptors on oncologic metastasis.

Wang R, Li S, Wang B, Wang G, Zheng H Am J Cancer Res. 2024; 14(9):4236-4247.

PMID: 39417177 PMC: 11477826. DOI: 10.62347/SCLS3277.


Melatonin, BAG-1 and cortisol circadian interactions in tumor pathogenesis and patterned immune responses.

Anderson G Explor Target Antitumor Ther. 2023; 4(5):962-993.

PMID: 37970210 PMC: 10645470. DOI: 10.37349/etat.2023.00176.

References
1.
Maher D, Wong W, White P, McKenna Jr R, Rosner H, Shamloo B . Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: a retrospective analysis. Br J Anaesth. 2014; 113 Suppl 1:i88-94. DOI: 10.1093/bja/aeu192. View

2.
Huang H, Benzonana L, Zhao H, Watts H, Perry N, Bevan C . Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination. Br J Cancer. 2014; 111(7):1338-49. PMC: 4183852. DOI: 10.1038/bjc.2014.426. View

3.
Singleton P, Mirzapoiazova T, Hasina R, Salgia R, Moss J . Increased μ-opioid receptor expression in metastatic lung cancer. Br J Anaesth. 2014; 113 Suppl 1:i103-8. PMC: 4111280. DOI: 10.1093/bja/aeu165. View

4.
Yang J, Bauer B, Wahner-Roedler D, Chon T, Xiao L . The Modified WHO Analgesic Ladder: Is It Appropriate for Chronic Non-Cancer Pain?. J Pain Res. 2020; 13:411-417. PMC: 7038776. DOI: 10.2147/JPR.S244173. View

5.
Zhang H, Qu M, Gorur A, Sun Z, Cata J, Chen W . Association of Mu-Opioid Receptor(MOR) Expression and Opioids Requirement With Survival in Patients With Stage I-III Pancreatic Ductal Adenocarcinoma. Front Oncol. 2021; 11:686877. PMC: 8249918. DOI: 10.3389/fonc.2021.686877. View